FDA Approves Sandoz' High-Concentration Version of Adalimuma

Both the high-concentration and low-concentration versions of adalimumab-adaz (Hyrimoz) injection will launch in July, along with a wave of other biosimilars to Humira (reference adalimumab).

Related Keywords

United States , America , Amgen Amjevita , Keren Haruvi , Samsung Bioepis , Sandoz Inc , North America , Celltrion Healthcare ,